MLchartDataset catalogue

Brentuximab

Term · Oncology and biomedicine · MLC-T-ONC-012109

A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.

Table 1. Record
IdentifierMLC-T-ONC-012109
FieldOncology and biomedicine
Synonymsanti-CD30 monoclonal antibody
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-012109",
  "term": "Brentuximab",
  "field": "Oncology and biomedicine",
  "definition": "A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.",
  "synonyms": [
    "anti-CD30 monoclonal antibody"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/brentuximab/"
}

Record 3,846 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.